<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544321</url>
  </required_header>
  <id_info>
    <org_study_id>15-1309</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02544321</nct_id>
  </id_info>
  <brief_title>Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes</brief_title>
  <official_title>Bromocriptine Quick Release (QR) as Adjunct Therapy in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes (T1D) continues to be a disease plagued by hyperglycemia, insulin resistance&#xD;
      (IR), and increased cardiovascular disease (CVD) despite advances in insulin delivery and&#xD;
      glucose monitoring. Therefore new approaches are needed. Bromocriptine (BC), a dopamine (DA)&#xD;
      agonist, has long been widely used for treating Parkinson's disease and prolactinoma. Its&#xD;
      recent approval in a quick release formulation, BCQR, for type 2 diabetes (T2D) is an&#xD;
      exciting development, representing a novel mechanism for improving IR. BCQR has not been&#xD;
      studied in T1D, but it's mechanism of action, mechanistic studies, and preliminary data&#xD;
      support the proposed study of possible benefits of BCQR on insulin action, glycemic control,&#xD;
      and the vasculature in T1D. This study has received an exemption from the FDA to study BCQR&#xD;
      in adults with T1D and an IND approval (131360) to study BCQR in adolescents with T1D. This&#xD;
      is a random-order, double-blind, placebo-controlled study of a 4 week intervention. Outcomes&#xD;
      will include fasting and postprandial glucose, glycemic variability, insulin dosing,&#xD;
      hypoglycemia frequency and awareness, sleep quality, and metabolic hormone levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Glucose</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, we will measure the effect of Bromocriptine Quick Release on average glucose levels (mg/dl) by continuous glucose monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Dosing</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, we will measure the effect of BCQR on insulin dosing (units//kg/day)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brachial Artery Distensibility</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, we will measure the brachial artery distensibility as a measure of vascular stiffness by Dynapulse (%/mmHg). A larger number indicates less stiffness (ie greater compliance).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyperemia Peripheral Arterial Tonometry (RH-PAT): Reactive Hyperemia Index (RHI)</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, we will measure the reactive hyperemia Index (RHI). The Reactive Hyperemia Index (RHI) measures increased bloodflow after vascular occlusion. Higher scores indicate lower CVD risk and a better outcome, Scores of less than 1.67 may be considered abnormal. Scores of 1.67 1.67-2.09 may be considered borderline, and scores of 2.10 or higher my be considered normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Glycemic Variability</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, we will measure the effect of Bromocriptine Quick Release on glycemic variability throughout the day (mg/dl), measured as SD of all glucose values throughout the last 7 days of intervention. Incorrectly initially entered as primary outcome. per protocol this has always been a secondary outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Awareness</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, we will measure Hypoglycemia Awareness using the Gold method (7 point Likert scale: Possible scores range from 1 to 7. higher scores indicate more impaired awareness of hypoglycemia, and a worse outcome), Clarke method (8 question questionnaire characterizing hypoglycemia awareness. Possible scores range from 0-7, with higher scores indicating less awareness and a worse outcome), and the McAuley score (list of symptoms with a 7 point Likert scale for each. Possible scores range from 1-7 for each item, and are averaged across all symptoms, for a total possible score range of 1-7, with higher scores indicating more symptom awareness, and a better outcome).&#xD;
Incorrectly initially entered as primary outcome. per protocol this has always been a secondary outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, the % will be measured by SyphgmoCor. The Augmentation Index measures vascular stiffness by comparing pulse pressure of the reflected wave to the primary wave. HIGHER scores indicate greater vascular stiffness and higher cardiovascular risk, but a normal range has not been clearly defined. Presented as AI normalized to a heart rate of 75 (AI75).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability (Adults)</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period we will measure the autonomic function by ECG. Ratio of maximum heart rate/minimum heartrate during a valsalva maneuver.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability (Adolescents)</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period we will measure the autonomic function by HRV measured by endopat and reported using the single gold standard measure of SDNN (standard deviation of beat to beat time interval). Normal is &gt;100, 50-100 indicates compromised autonomic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Duration</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, measurements of sleep duration on weekdays and weekends (minutes) by a Philips Spectrum Plus sleep monitor will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, measurements of sleep efficiency (percent of time in bed spent asleep) during the week and on weekends by a Philips Spectrum Plus sleep monitor will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Markers-glucose and Triglycerides</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Markers-fatty Acids</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Markers-glucagon</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Markers - GLP1</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Markers - Insulin</measure>
    <time_frame>4 weeks</time_frame>
    <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Bromocriptine QR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 weeks of investigational drug Bromocriptine QR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 weeks of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromocriptine</intervention_name>
    <arm_group_label>Bromocriptine QR</arm_group_label>
    <other_name>Bromocriptine Quick Release (BCQR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 1 Diabetes (T1D) of &gt;1 year duration based on a clinical course consistent with&#xD;
             T1D and rapid conversion to insulin requirement after diagnosis.&#xD;
&#xD;
          2. HbA1c 6.5-10% (adults) or any HbA1c up to 12% (pediatrics)&#xD;
&#xD;
          3. age 12-60 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any comorbid condition associated with inflammation, insulin resistance, or&#xD;
             dyslipidemia including cancer, heart failure, active or end stage liver disease,&#xD;
             kidney disease (except microalbuminuria), inadequately treated thyroid disease, or&#xD;
             rheumatologic disease;&#xD;
&#xD;
          2. Tobacco or marijuana use;&#xD;
&#xD;
          3. Pregnancy;&#xD;
&#xD;
          4. Regular or frequent oral steroid use;&#xD;
&#xD;
          5. Current use of insulin sensitizing medications, neuroleptics, ergot-related&#xD;
             medications, or triptan medications for migraine,&#xD;
&#xD;
          6. Diagnosis or history of psychosis,&#xD;
&#xD;
          7. Diabetes of other cause such as Maturity Onset Diabetes of the Young or cystic&#xD;
             fibrosis-related diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Schauer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristen Nadeau, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado/University of Colorado</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado-Denver, Anshutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <results_first_submitted>July 12, 2021</results_first_submitted>
  <results_first_submitted_qc>August 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2021</results_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromocriptine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02544321/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Some participants screen failed or withdrew from the study after enrollment, but prior to starting the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bromocriptine QR, Then Placebo</title>
          <description>4 weeks of investigational drug Bromocriptine QR, then 4 weeks of placebo.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Bromocriptine QR</title>
          <description>4 weeks of placebo, then 4 weeks of investigational drug Bromocriptine QR</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed First Treatment</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Washout</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Second Treatment</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all subjects who completed at least one phase of the study</population>
      <group_list>
        <group group_id="B1">
          <title>Bromocriptine QR, Then Placebo</title>
          <description>4 weeks of investigational drug Bromocriptine QR, then 4 weeks of placebo.</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Then Bromocriptine QR</title>
          <description>4 weeks of placebo, then 4 weeks of investigational drug Bromocriptine QR</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Adults and adolescents are divided by rows</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Adults</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.1" spread="9.0"/>
                    <measurement group_id="B2" value="38" spread="10.0"/>
                    <measurement group_id="B3" value="41.1" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adolescents</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.5" spread="2.8"/>
                    <measurement group_id="B2" value="15.6" spread="2.7"/>
                    <measurement group_id="B3" value="16.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Adults and adolescents are divided by rows</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Adults</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adolescents</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Adults and adolescents are divided by rows</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Adults</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adolescents</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Adults and adolescents are divided by rows</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Adults</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adolescents</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Glucose</title>
        <description>At the end of each 4 week intervention period, we will measure the effect of Bromocriptine Quick Release on average glucose levels (mg/dl) by continuous glucose monitoring</description>
        <time_frame>4 weeks</time_frame>
        <population>Data reflects average glucose levels.</population>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose</title>
          <description>At the end of each 4 week intervention period, we will measure the effect of Bromocriptine Quick Release on average glucose levels (mg/dl) by continuous glucose monitoring</description>
          <population>Data reflects average glucose levels.</population>
          <units>mg/dl</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182" spread="5"/>
                    <measurement group_id="O2" value="165" spread="5"/>
                    <measurement group_id="O3" value="181" spread="5"/>
                    <measurement group_id="O4" value="165" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Dosing</title>
        <description>At the end of each 4 week intervention period, we will measure the effect of BCQR on insulin dosing (units//kg/day)</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Dosing</title>
          <description>At the end of each 4 week intervention period, we will measure the effect of BCQR on insulin dosing (units//kg/day)</description>
          <units>units//kg/day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread=".03"/>
                    <measurement group_id="O2" value="0.54" spread=".02"/>
                    <measurement group_id="O3" value="0.88" spread=".03"/>
                    <measurement group_id="O4" value="0.56" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Brachial Artery Distensibility</title>
        <description>At the end of each 4 week intervention period, we will measure the brachial artery distensibility as a measure of vascular stiffness by Dynapulse (%/mmHg). A larger number indicates less stiffness (ie greater compliance).</description>
        <time_frame>4 weeks</time_frame>
        <population>Compared for placebo versus BCQR after 4 weeks of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Brachial Artery Distensibility</title>
          <description>At the end of each 4 week intervention period, we will measure the brachial artery distensibility as a measure of vascular stiffness by Dynapulse (%/mmHg). A larger number indicates less stiffness (ie greater compliance).</description>
          <population>Compared for placebo versus BCQR after 4 weeks of treatment.</population>
          <units>%/mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="0.19"/>
                    <measurement group_id="O2" value="6.2" spread="0.2"/>
                    <measurement group_id="O3" value="6.14" spread="0.19"/>
                    <measurement group_id="O4" value="6.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hyperemia Peripheral Arterial Tonometry (RH-PAT): Reactive Hyperemia Index (RHI)</title>
        <description>At the end of each 4 week intervention period, we will measure the reactive hyperemia Index (RHI). The Reactive Hyperemia Index (RHI) measures increased bloodflow after vascular occlusion. Higher scores indicate lower CVD risk and a better outcome, Scores of less than 1.67 may be considered abnormal. Scores of 1.67 1.67-2.09 may be considered borderline, and scores of 2.10 or higher my be considered normal.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperemia Peripheral Arterial Tonometry (RH-PAT): Reactive Hyperemia Index (RHI)</title>
          <description>At the end of each 4 week intervention period, we will measure the reactive hyperemia Index (RHI). The Reactive Hyperemia Index (RHI) measures increased bloodflow after vascular occlusion. Higher scores indicate lower CVD risk and a better outcome, Scores of less than 1.67 may be considered abnormal. Scores of 1.67 1.67-2.09 may be considered borderline, and scores of 2.10 or higher my be considered normal.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.09"/>
                    <measurement group_id="O2" value="2.1" spread="0.1"/>
                    <measurement group_id="O3" value="2.24" spread="0.09"/>
                    <measurement group_id="O4" value="2.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glycemic Variability</title>
        <description>At the end of each 4 week intervention period, we will measure the effect of Bromocriptine Quick Release on glycemic variability throughout the day (mg/dl), measured as SD of all glucose values throughout the last 7 days of intervention. Incorrectly initially entered as primary outcome. per protocol this has always been a secondary outcome.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glycemic Variability</title>
          <description>At the end of each 4 week intervention period, we will measure the effect of Bromocriptine Quick Release on glycemic variability throughout the day (mg/dl), measured as SD of all glucose values throughout the last 7 days of intervention. Incorrectly initially entered as primary outcome. per protocol this has always been a secondary outcome.</description>
          <units>mg/dl</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="2.1"/>
                    <measurement group_id="O2" value="61" spread="2.5"/>
                    <measurement group_id="O3" value="73" spread="2.1"/>
                    <measurement group_id="O4" value="63" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia Awareness</title>
        <description>At the end of each 4 week intervention period, we will measure Hypoglycemia Awareness using the Gold method (7 point Likert scale: Possible scores range from 1 to 7. higher scores indicate more impaired awareness of hypoglycemia, and a worse outcome), Clarke method (8 question questionnaire characterizing hypoglycemia awareness. Possible scores range from 0-7, with higher scores indicating less awareness and a worse outcome), and the McAuley score (list of symptoms with a 7 point Likert scale for each. Possible scores range from 1-7 for each item, and are averaged across all symptoms, for a total possible score range of 1-7, with higher scores indicating more symptom awareness, and a better outcome).&#xD;
Incorrectly initially entered as primary outcome. per protocol this has always been a secondary outcome.</description>
        <time_frame>4 weeks</time_frame>
        <population>Unadjusted least square means by mixed procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Awareness</title>
          <description>At the end of each 4 week intervention period, we will measure Hypoglycemia Awareness using the Gold method (7 point Likert scale: Possible scores range from 1 to 7. higher scores indicate more impaired awareness of hypoglycemia, and a worse outcome), Clarke method (8 question questionnaire characterizing hypoglycemia awareness. Possible scores range from 0-7, with higher scores indicating less awareness and a worse outcome), and the McAuley score (list of symptoms with a 7 point Likert scale for each. Possible scores range from 1-7 for each item, and are averaged across all symptoms, for a total possible score range of 1-7, with higher scores indicating more symptom awareness, and a better outcome).&#xD;
Incorrectly initially entered as primary outcome. per protocol this has always been a secondary outcome.</description>
          <population>Unadjusted least square means by mixed procedure.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gold method scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="1.31"/>
                    <measurement group_id="O2" value="3.02" spread="1.67"/>
                    <measurement group_id="O3" value="2.00" spread="1.18"/>
                    <measurement group_id="O4" value="3.15" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clarke method scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="1.23"/>
                    <measurement group_id="O2" value="2.33" spread="1.90"/>
                    <measurement group_id="O3" value="1.33" spread="1.20"/>
                    <measurement group_id="O4" value="2.67" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>McAuley score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.22"/>
                    <measurement group_id="O2" value="3.40" spread="0.31"/>
                    <measurement group_id="O3" value="3.21" spread="0.22"/>
                    <measurement group_id="O4" value="2.90" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Augmentation Index</title>
        <description>At the end of each 4 week intervention period, the % will be measured by SyphgmoCor. The Augmentation Index measures vascular stiffness by comparing pulse pressure of the reflected wave to the primary wave. HIGHER scores indicate greater vascular stiffness and higher cardiovascular risk, but a normal range has not been clearly defined. Presented as AI normalized to a heart rate of 75 (AI75).</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Augmentation Index</title>
          <description>At the end of each 4 week intervention period, the % will be measured by SyphgmoCor. The Augmentation Index measures vascular stiffness by comparing pulse pressure of the reflected wave to the primary wave. HIGHER scores indicate greater vascular stiffness and higher cardiovascular risk, but a normal range has not been clearly defined. Presented as AI normalized to a heart rate of 75 (AI75).</description>
          <units>Percentage of pressure wave</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.42" spread="1.71"/>
                    <measurement group_id="O2" value="-2.0" spread="1.8"/>
                    <measurement group_id="O3" value="12.52" spread="1.72"/>
                    <measurement group_id="O4" value="-2.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate Variability (Adults)</title>
        <description>At the end of each 4 week intervention period we will measure the autonomic function by ECG. Ratio of maximum heart rate/minimum heartrate during a valsalva maneuver.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Variability (Adults)</title>
          <description>At the end of each 4 week intervention period we will measure the autonomic function by ECG. Ratio of maximum heart rate/minimum heartrate during a valsalva maneuver.</description>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.05"/>
                    <measurement group_id="O2" value="1.14" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate Variability (Adolescents)</title>
        <description>At the end of each 4 week intervention period we will measure the autonomic function by HRV measured by endopat and reported using the single gold standard measure of SDNN (standard deviation of beat to beat time interval). Normal is &gt;100, 50-100 indicates compromised autonomic function.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Variability (Adolescents)</title>
          <description>At the end of each 4 week intervention period we will measure the autonomic function by HRV measured by endopat and reported using the single gold standard measure of SDNN (standard deviation of beat to beat time interval). Normal is &gt;100, 50-100 indicates compromised autonomic function.</description>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" spread="5"/>
                    <measurement group_id="O2" value="76.4" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Duration</title>
        <description>At the end of each 4 week intervention period, measurements of sleep duration on weekdays and weekends (minutes) by a Philips Spectrum Plus sleep monitor will be obtained.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Duration</title>
          <description>At the end of each 4 week intervention period, measurements of sleep duration on weekdays and weekends (minutes) by a Philips Spectrum Plus sleep monitor will be obtained.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>weekdays</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433" spread="69"/>
                    <measurement group_id="O2" value="394" spread="59"/>
                    <measurement group_id="O3" value="414" spread="47"/>
                    <measurement group_id="O4" value="402" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>weekends</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486" spread="81"/>
                    <measurement group_id="O2" value="458" spread="95"/>
                    <measurement group_id="O3" value="464" spread="85"/>
                    <measurement group_id="O4" value="453" spread="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality</title>
        <description>At the end of each 4 week intervention period, measurements of sleep efficiency (percent of time in bed spent asleep) during the week and on weekends by a Philips Spectrum Plus sleep monitor will be obtained.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality</title>
          <description>At the end of each 4 week intervention period, measurements of sleep efficiency (percent of time in bed spent asleep) during the week and on weekends by a Philips Spectrum Plus sleep monitor will be obtained.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>efficiency during the week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9" spread="5.3"/>
                    <measurement group_id="O2" value="90.4" spread="4.2"/>
                    <measurement group_id="O3" value="89.0" spread="4.1"/>
                    <measurement group_id="O4" value="90.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>efficiency weekends</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3" spread="4.8"/>
                    <measurement group_id="O2" value="89.7" spread="5.0"/>
                    <measurement group_id="O3" value="89.0" spread="5.4"/>
                    <measurement group_id="O4" value="90.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Markers-glucose and Triglycerides</title>
        <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
        <time_frame>4 weeks</time_frame>
        <population>glucose and triglyceride total AUC least square means +/- SD</population>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Markers-glucose and Triglycerides</title>
          <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
          <population>glucose and triglyceride total AUC least square means +/- SD</population>
          <units>mg*hr/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11735" spread="7180"/>
                    <measurement group_id="O2" value="9228" spread="5530"/>
                    <measurement group_id="O3" value="11356" spread="5990"/>
                    <measurement group_id="O4" value="12357" spread="6962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3452" spread="2878"/>
                    <measurement group_id="O2" value="3445" spread="4582"/>
                    <measurement group_id="O3" value="3066" spread="2040"/>
                    <measurement group_id="O4" value="3460" spread="4634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Markers-fatty Acids</title>
        <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
        <time_frame>4 weeks</time_frame>
        <population>Non-esterified fatty acids total AUC least square means +/- SD</population>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Markers-fatty Acids</title>
          <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
          <population>Non-esterified fatty acids total AUC least square means +/- SD</population>
          <units>microEq*hr/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123334" spread="115005"/>
                    <measurement group_id="O2" value="75561" spread="52616"/>
                    <measurement group_id="O3" value="93661" spread="58385"/>
                    <measurement group_id="O4" value="67497" spread="46017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Markers-glucagon</title>
        <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
        <time_frame>4 weeks</time_frame>
        <population>glucagon total AUC least square means +/- SE</population>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Markers-glucagon</title>
          <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
          <population>glucagon total AUC least square means +/- SE</population>
          <units>pg*hr/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2398" spread="1959"/>
                    <measurement group_id="O2" value="2160" spread="1361"/>
                    <measurement group_id="O3" value="2011" spread="1252"/>
                    <measurement group_id="O4" value="2350" spread="1491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Markers - GLP1</title>
        <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
        <time_frame>4 weeks</time_frame>
        <population>GLP-1 total AUC least square means +/- SD</population>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Markers - GLP1</title>
          <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
          <population>GLP-1 total AUC least square means +/- SD</population>
          <units>pmol*hr/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="661" spread="435"/>
                    <measurement group_id="O2" value="872" spread="563"/>
                    <measurement group_id="O3" value="766" spread="392"/>
                    <measurement group_id="O4" value="1196" spread="728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Markers - Insulin</title>
        <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
        <time_frame>4 weeks</time_frame>
        <population>insulin total AUC least square means +/- SD</population>
        <group_list>
          <group group_id="O1">
            <title>Bromocriptine QR (Adolescents)</title>
            <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
          </group>
          <group group_id="O2">
            <title>Bromocriptine QR (Adults)</title>
            <description>4 weeks of investigational drug Bromocriptine QR</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Adolescents)</title>
            <description>4 weeks of placebo&#xD;
Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Adults)</title>
            <description>4 weeks of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Markers - Insulin</title>
          <description>At the end of each 4 week intervention period, glucose, insulin, triglycerides, NEFA, GLP-1, and glucagon area under the curve will be measured during Mixed Meal Tolerance Test.</description>
          <population>insulin total AUC least square means +/- SD</population>
          <units>microIU*hr/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4162" spread="2496"/>
                    <measurement group_id="O2" value="2386" spread="1087"/>
                    <measurement group_id="O3" value="4001" spread="3209"/>
                    <measurement group_id="O4" value="2379" spread="1160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bromocriptine QR (Adolescents)</title>
          <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
        </group>
        <group group_id="E2">
          <title>Bromocriptine QR (Adults)</title>
          <description>4 weeks of investigational drug Bromocriptine QR&#xD;
Bromocriptine</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Adolescents)</title>
          <description>4 weeks of placebo&#xD;
Placebo</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Adults)</title>
          <description>4 weeks of placebo&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>severe hypoglycemia</sub_title>
                <description>participant had episode of severe hypoglycemia working at high altitude as a diabetes camp counselor without adjusting insulin dosing as instructed for the change in altitude/activity Event resolved without sequelae.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>diagnosed with RA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>shortly after dose. only caused one w/d.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>orthostasis</sub_title>
                <description>occurred shortly after dosing. not sever enough to cause d/c.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Irene Schauer, MD</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>3037241111</phone>
      <email>clinicalresearchsupportcenter@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

